摘要
目的探究急性脑梗死患者分别采用阿替普酶与尿激酶药物治疗的效果。方法研究对象为80例急性脑梗死患者,研究时间为2016年12月—2019年12月,按照治疗药物不同予以分组,对照组(n=40)采用尿激酶治疗,治疗组(n=40)采用阿替普酶治疗,对比两组患者的临床治疗效果、美国国立卫生院卒中量表(the National Institutes of Health stroke scale,NIHSS)评分、并发症发生情况、改良RANKIN量表(modified rankin scale,mRS)评分等指标数据。结果治疗后,治疗组患者的临床治疗效果高于对照组,NIHSS评分、mRS评分和并发症发生率均低于对照组,比较差异均有统计学意义(P <0.05)。结论针对急性脑梗死患者采用两种不同药物治疗,治疗效果不同,阿替普酶的治疗效果高于尿激酶的治疗效果,且神经功能改善效果良好,并发症发生率低,具有较高的安全性。
Objective To explore the therapeutic effect of ateplase and urokinase in patients with acute cerebral infarction.Methods From December 2016 to December 2019,80 patients with acute cerebral infarction were studied and were divided into two groups according to the different treatment drugs.The control group(n=40)was treated with urokinase,and the treatment group(n=40)was treated with alteplase.The clinical therapeutic effect,NIHSS score,the incidence of complications and mRS score of the two groups were compared.Results After treatment,the clinical treatment effect of the patients in the treatment group was higher than that of the control group,and the NIHSS score,mRS score,and incidence of complications in the treatment group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Two different drugs are used to treat the patients with acute cerebral infarction,the therapeutic effect is different,that is,the therapeutic effect of ateplase is higher than that of urokinase,and the effect of nerve function improvement is good,the incidence of complications is low,and the safety is high.
作者
冯淼玲
FENG Miaoling(Department of Nephrology,Meizhou People's Hospital,Meizhou Guangdong 514500,China)
出处
《中国卫生标准管理》
2020年第18期88-90,共3页
China Health Standard Management